Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

BTIG analyst David Larsen maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of $85.00.

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Maple Grove-based Morari Medical’s device “MOR” is a drug- and chemical-free approach for the common men’s sexual health ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

AJ Toler was taken aback by Hims’ scathing criticism of obesity in their weight-loss drug Super Bowl commercial.

Erectile dysfunction (ED) is a common issue that affects millions of men, leading to a decline in quality of life and ...